Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors

Reference

• BLACK, A. E., HAYES, R. N., ROTH, B. D., Woo, P. and WOOLF, T. F., 1999, Metabolism and excretion of atorvastatin in rats and dogs. Drug Metabolism and Disposition, 27, 640–652.
   Web of Science ®Google Scholar
• BOBERG, M., ANGERBAUER, R., KANHAI, W. K., KARL, W., KERN, A. and RADTKE, M., 1998, Biotransformation of cerivastatin in mice, rats, and dogs in vivo. Drug Metabolism and Disposition, 26, 640–652.
   PubMed Web of Science ®Google Scholar
• BROWN, B. G., ZHAO, X. Q., SACCO, D. E. and ALBERS, J. J., 1993, Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation, 87, 1781–1791.
   PubMed Web of Science ®Google Scholar
• CHRISTIANS, U., JACOBSEN, W. and FLOREN, L., 1998, Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor in transplant patients: are the statins mechanistically similar? Pharmacology Therapy, 80, 1–34.
   PubMed Web of Science ®Google Scholar
• COOPER, K. J., MARTIN, P. D., DANE, A. L., WARWICK, M. J. and SCHNECK, D. W., 2002, The effect of fiuconazole on the pharmacokinetics of rosuvastatin. European Journal of Clinical Pharmacology, 58, 527–531.
   PubMed Web of Science ®Google Scholar
• DAIN, J. G., Fu, E., GORSKI, J., NICOLETTI, J. and SCALLEN, T. J., 1993, Biotransformation of fiuvastatin sodium in humans. Drug Metabolism and Disposition, 21, 567–572.
   PubMed Web of Science ®Google Scholar
• FISHER, V., JOHANSON, L., HEITZ, F., TULLMAN, R., GRAHAM, E. and BALDECK, J. P., 1999, The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fiuvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metabolism and Disposition, 27, 410–416.
   PubMed Web of Science ®Google Scholar
• FUJINO, H., KOJIMA, J., YAMADA, Y., KANDA, H. and KIMATA, H., 1999a, Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4): Interspecies variation in laboratory animals and humans. Xenobiotic Metabolism and Disposition, 14, 79–91.
   Google Scholar
• FUJINO, H., YAMADA, I., HIRANO, M. and YONEDA, M., 1999b, Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and human. Xenobiotic Metabolism and Disposition, 14, 415–424.
   Google Scholar
• FUJINO, H., YAMADA, I., SHIMADA, S. and YONEDA, M., 2001, Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin-layer chromatography radioactive assay - inhibitory effect of NK-104, a new inhibitor of HMG-CoA reductase. Journal of Chromatography B, 757, 143–150.
   PubMed Web of Science ®Google Scholar
• FUJINO, H., YAMADA, I., SHIMADA, S., YONEDA, M. and KOJIMA, J., 2003, Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica, 33, 27–41.
   PubMed Web of Science ®Google Scholar
• GREENSPAN, M. D., YUDKOVITZ, J. B., ALBELTS, A. W., ARGENBRIGHT, L. S., ARISON, B. H. and SMITH, J. L., 1988, Metabolism of lovastatin by rat and human liver microsomes in vitro. Drug Metabolism and Disposition, 16, 768–782.
   Web of Science ®Google Scholar
• HAVEL, R. J. and RAPAPORT, E., 1995, Management of primary hyperlipidemia. New England Journal of Medicine, 332, 1301–1307.
   Web of Science ®Google Scholar
• HULL, C. K., PENMAN, A. D., SMITH, C. K. and MARTIN, P. D., 2002, Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection. Journal of Chromatography B, 772, 219–228.
   PubMed Web of Science ®Google Scholar
• ISHIGAMI, M., HONDA, T., TAKASAKI, W., IKEDA, T., KOMAI, T. and ITo, K., 2001, A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metabolism and Disposition, 29, 282–288.
   PubMed Web of Science ®Google Scholar
• JACOBSEN, W., KUHN, B., SOLDNER, A., KIRCHNER, G., SEWING, K.F. and KOLLMAN, P. A., 2000, Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metabolism and Disposition, 28, 1369–1378.
   PubMed Web of Science ®Google Scholar
• JEMAL, M., RAO, S. and SALAHUDEEN, I., 1999a, Quantitation of cerivastatin and its seven acid and lactone biotransformation products in human serum by liquid chromatography-electrospray tandem mass spectrometry. Journal of Chromatography B, 736, 19–41.
   PubMed Web of Science ®Google Scholar
• JEMAL, M., OUYANG, Z. and CHEN, B. C., 1999b, Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 13, 1003–1015.
   PubMed Web of Science ®Google Scholar
• KANTOLA, T., KIVISTO, K. T. and NEUVONEN, P. J., 1998, Effect of itraconazole on the pharmacokinetics of atorvastatin. Clinical Pharmacology and Therapeutics, 64, 58–65.
   PubMed Web of Science ®Google Scholar
• KAJINAMI, K., Koizumi, J., UEDA, K., MIYAMOTO, S., TAKEGOSHI, T. and MABUCHI, H., 2000, Effect of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 study group. American Journal of Cardiology, 15, 178–183.
   Web of Science ®Google Scholar
• KAJINAMI, K., TAKEGOSHI, N. and SAITO, Y., 2003, Pitavastatin: Efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovascular Drug Reviews, 21, 199–215.
   PubMed Web of Science ®Google Scholar
• KIMATA, H., FUJINO, H., KOIDE, T., YAMADA, Y., TSUNENARI, Y. and YONEMITSU, M., 1998, Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats. Xenobiotic Metabolism and Disposition, 13,484–498.
   Google Scholar
• KOJIMA, J., FUJINO, H., YOSHIMURA, M., MORIKAWA, H. and KIMATA, H., 1999, Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B, 724, 173–180.
   PubMed Web of Science ®Google Scholar
• LILJA, J. J., KIVISTO, K. T. and NEUVONEN, P. J., 1998, Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clinical Pharmacology and Therapy, 64, 477–483.
   PubMed Web of Science ®Google Scholar
• LILJA, J. J., KIVISTO, K. T. and NEUVONEN, P. J., 1999, Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clinical Pharmacology and Therapy, 66, 118–127.
   PubMed Web of Science ®Google Scholar
• LUDWIG, E., WOLFINGER, H. and EBNER, T., 1998, Assessment of microsomal tolbutamide hydroxylation by a simple thin-layer chromatography radioactivity assay. Journal of Chromatography B, 707, 347–350.
   PubMed Web of Science ®Google Scholar
• MUCK, R. J., 2000, Clinical pharmacokinetics of cerivastatin. Clinical Pharmacokinetics, 39, 99–116.
   PubMed Web of Science ®Google Scholar
• NEZAKA, K., TAKAO, A., KIMURA, K., TAKAICHI, M., INAZAWA, K. and KOIKE, M., 2002, Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. Xenobiotica, 32, 715–727.
   PubMed Web of Science ®Google Scholar
• PAOLETTI, R., CORSINI, A. and BELLOSTA, S., 2002, Pharmacological interactions of statins. Atherosclerosis Supplement, 3, 35–40.
   PubMed Web of Science ®Google Scholar
• PRUEKSARITANONT, T., GORHAM, L. M., MA, B., Liu, L., Yu, X., ZHAO, J. J., SLAUGHTER, D. E., ARISON, B. H. and VYAS, K. P., 1997, In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metabolism and Disposition, 25, 1191–1199.
   PubMed Web of Science ®Google Scholar
• PRUEKSARITANONT, T., SUBRAMANIAN, R., FANG, X., MA, B., Qui, Y. and LIN, J. H., 2002, Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metabolism and Disposition, 30, 505–512.
   PubMed Web of Science ®Google Scholar
• PETERSON, J. E. and GRAHAM-LORENCE, S. E., 1995, Bacterial P450s. Structural similarities and functional differences, in cytochrome P450. In P. R. Ortiz de Montellano (Ed.) Structure, Mechanism, and Biochemistry, 2nd edn (New York: Prenum), pp. 152–182.
   Google Scholar
• WILLIAMS, D. and FEELY, J., 2002, Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clinical Pharmacokinetics, 41, 343–370.
   PubMed Web of Science ®Google Scholar
• YAMADA, I., FUJINO, H., SHIMADA, S. and KOJIMA, J., 2003, Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: similarities and difference in the metabolism of pitavastatin in monkeys and humans. Xenobiotica, 33, 789–803.
   PubMed Web of Science ®Google Scholar